Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | FABP4 | P15090 | 4/20 | 0.37 |
| ▸ | TTR | P02766 | 2/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | CMA1 | P23946 | 1/20 | 0.36 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CASP6 | P55212 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15461563 | 0.84 | PTPN11 (0.38) | HSD11B1PTPN11CMA1SCN9ACA1 | |
| SCHEMBL9954422 | 0.82 | CA2 (0.47) | HSD11B1PTPN11CDK2CA1CA2 | |
| SCHEMBL9953261 | 0.82 | PTPN11 (0.38) | HSD11B1PTPN11FABP4CMA1SCN9A | |
| SCHEMBL2443891 | 0.78 | HSD11B1 (0.41) | HSD11B1PTPN11CMA1SCN9A | |
| SCHEMBL2904147 | 0.71 | RORC (0.45) | MYCHSD11B1FABP4TTRCYP1A2 | |
| SCHEMBL2052186 | 0.71 | CYP1A2 (0.38) | CDK2CMA1CYP1A2CA1CA2 | |
| SCHEMBL932002 | 0.69 | NR4A1 (0.46) | FABP4CMA1NR4A1 | |
| SCHEMBL30082300 | 0.69 | NR4A1 (0.46) | FABP4CMA1NR4A1 | |
| SCHEMBL19903069 | 0.69 | CMA1 (0.38) | CMA1 | |
| SCHEMBL3597395 | 0.69 | KEAP1 (0.53) | PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551999-B2 | Heterocyclic compound and pharmaceutical composition thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| CN-103224488-A | Heterocyclic compound or salt thereof | OTSUKA PHARMA CO LTD | 2013-07-31 | — | — | CN | disclosed |
| EP-2207773-B1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMA CO LTD (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20100261720-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-10-14 | — | — | US | disclosed |
| CN-101842367-A | Heterocyclic compounds and pharmaceutical compositions thereof | OTSUKA PHARMA CO LTD | 2010-09-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261720-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | COL1A1, COL2A1, COL14A1 | MYC 862/4885HSD11B1 127/4885PTPN11 2540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.